PLA2G7: A Protein with Multiple Functions and Potential as A Drug Target

Target Name: PLA2G7

NCBI ID: G7941

PLA2G7: A Protein with Multiple Functions and Potential as A Drug Target

PLA2G7 (Pro-lylated advanced G protein-coupled receptor 7) is a protein that is expressed in various tissues and cells in the body. It is a member of the G protein-coupled receptor (GPCR) family, which is a large superfamily of transmembrane proteins that play a key role in cellular signaling. PLA2G7 is characterized by its unique structure, which consists of a long extracellular domain, a short transmembrane region, and a short intracellular tail.

One of the key functions of PLA2G7 is its role in cell signaling. It is involved in a wide range of physiological processes in the body, including cell adhesion, migration, and signaling pathways that regulate cell behavior. PLA2G7 has been shown to play a key role in the regulation of neurotransmitter release from neurons, which is critical for a wide range of brain function.

PLA2G7 is also of interest as a potential drug target. Due to its involvement in multiple cellular signaling pathways, PLA2G7 has been identified as a potential target for a variety of drugs, including neurotransmitter antagonists, kinase inhibitors, and GPCR antagonists. Several PLA2G7-targeted drugs are currently in development, including small molecule inhibitors and monoclonal antibodies.

In addition to its potential as a drug target, PLA2G7 is also of interest as a biomarker. Its expression is regulated by a variety of factors, including cytokines, chemokines, and signaling pathways that are involved in cell signaling. This makes PLA2G7 an attractive candidate for use as a biomarker for a wide range of diseases, including neurodegenerative disorders, pain, and cancer.

PLA2G7 is also of interest as a potential therapeutic target for a variety of diseases. Its involvement in multiple cellular signaling pathways makes it a potential target for a wide range of drugs, including neurotransmitter antagonists, kinase inhibitors, and GPCR antagonists. Several PLA2G7-targeted drugs are currently in development, including small molecule inhibitors and monoclonal antibodies. These drugs have the potential to treat a wide range of diseases, including neurodegenerative disorders, pain, and cancer.

In conclusion, PLA2G7 is a protein that is of interest as a drug target and biomarker. Its unique structure and multiple functions make it a potential target for a wide range of drugs, including neurotransmitter antagonists, kinase inhibitors, and GPCR antagonists. Its potential as a biomarker for a variety of diseases, as well as its potential as a therapeutic target for a wide range of conditions, makes PLA2G7 a promising molecule for further study and development.

Protein Name: Phospholipase A2 Group VII

Functions: Lipoprotein-associated calcium-independent phospholipase A2 involved in phospholipid catabolism during inflammatory and oxidative stress response (PubMed:7700381, PubMed:8624782, PubMed:2040620, PubMed:16371369, PubMed:17090529, PubMed:10066756). At the lipid-aqueous interface, hydrolyzes the ester bond of fatty acyl group attached at sn-2 position of phospholipids (phospholipase A2 activity) (PubMed:2040620, PubMed:10504265). Specifically targets phospholipids with a short-chain fatty acyl group at sn-2 position (PubMed:2040620). Can hydrolyze phospholipids with long fatty acyl chains, only if they carry oxidized functional groups (PubMed:2040620, PubMed:8624782). Hydrolyzes and inactivates platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine), a potent pro-inflammatory signaling lipid that acts through PTAFR on various innate immune cells (PubMed:10504265, PubMed:10066756, PubMed:7592717, PubMed:11590221, PubMed:7700381, PubMed:18434304, PubMed:16371369, PubMed:8675689, PubMed:8624782). Hydrolyzes oxidatively truncated phospholipids carrying an aldehyde group at omega position, preventing their accumulation in low-density lipoprotein (LDL) particles and uncontrolled pro-inflammatory effects (PubMed:2040620, PubMed:7700381). As part of high-density lipoprotein (HDL) particles, can hydrolyze phospholipids having long-chain fatty acyl hydroperoxides at sn-2 position and protect against potential accumulation of these oxylipins in the vascular wall (PubMed:17090529). Catalyzes the release from membrane phospholipids of F2-isoprostanes, lipid biomarkers of cellular oxidative damage (PubMed:16371369)

More Common Targets